Physician profile
Tammy Murphy
NPI 1760767776
$278.96
in general payments reported to CMS, 2019-2025
12 companies · $245 in 2025
The $245 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $33.78 · 2025: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $245 · Education: $33.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $245.18 |
| Education | $33.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $36.10 | 2025 | Ozempic, Wegovy |
| Travere Therapeutics, INC. | $33.78 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.55 | 2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $23.50 | 2025 | Spravato |
| Abbvie INC. | $21.93 | 2025 | |
| Dexcom, INC. | $21.75 | 2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $21.14 | 2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $19.35 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $19.29 | 2025 | Airsupra |
| Astellas Pharma US INC | $18.89 | 2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $16.11 | 2025 | Rexulti |
| Lilly USA, LLC | $15.57 | 2025 | Zepbound, Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tammy Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.